Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorBussini, Linda
dc.contributor.authorRosselli Del Turco, Elena
dc.contributor.authorPasquini, Zeno
dc.contributor.authorScolz, Kristian
dc.contributor.authorAmedeo, Alberto
dc.contributor.authorBeci, Giacomo
dc.contributor.authorPericàs Pulido, Juan Manuel
dc.date.accessioned2022-09-07T11:48:02Z
dc.date.available2022-09-07T11:48:02Z
dc.date.issued2022-06
dc.identifier.citationBussini L, Rosselli Del Turco E, Pasquini Z, Scolz K, Amedeo A, Beci G, et al. Risk factors for persistent enterococcal bacteraemia: a multicentre retrospective study. J Glob Antimicrob Resist. 2022 Jun;29:386–9.
dc.identifier.issn2213-7165
dc.identifier.urihttp://hdl.handle.net/11351/8051
dc.descriptionEnterococcal bacteraemia; Enterococcus; Persistent bacteraemia
dc.description.abstractObjectives Conditions favouring persistent enterococcal bacteraemia (p-EB) have not been fully investigated yet. The aim of our study is to analyse risk factors for p-EB and its impact on mortality. Methods International two-centre retrospective study of all hospitalised adults with enterococcal bacteraemia managed with follow-up blood cultures (BCs) during the period 2011–2019. Exclusion criteria were: (1) death within 72 hours from index BCs and (2) polymicrobial bacteraemia. Primary endpoint was p-EB, defined as further isolation of the same species of Enterococcus spp. from BCs after at least 72 hours of appropriate antibiotic therapy. Multivariable logistic regression model was performed to assess risk factors for p-EB. The impact of p-EB on 30-day mortality was assessed by Kaplan-Meier survival curve and Cox regression multivariable model. Results During the study period, 244 enterococcal bacteraemia were diagnosed. P-EB were 13.5% (33/244). At multivariable analysis, factors independently associated with p-EB were hematologic malignancy (OR 4.60 [95% CI 1.32–16.00], P = 0.01), infective endocarditis (OR 7.99 [95% CI 2.20–28.9], P = 0.002), and use of daptomycin as initial treatment (OR 4.50 [95% CI 1.29–15.61], P = 0.018). Mortality rate was higher in the p-EB group (32% vs. 18%). Kaplan-Meier survival curve showed that patients with p-EB were less likely to survive at 30 days from index BCs (log-rank P = 0.002). Using a Cox regression model, independent predictors of 30-day mortality were hematologic malignancy (HR 2.30 [95% CI 1.02–4.11], P = 0.043), p-EB (HR 1.93 [95% CI 0.92–4.04], P = 0.08), and septic shock (HR 5.92 [95% CI 2.17–16.30], P = 0.001). Conclusion P-EB was diagnosed mainly in very fragile patients and in those receiving daptomycin as frontline therapy. P-EB may have an impact on mortality.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesJournal of Global Antimicrobial Resistance;29
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectBacterièmia - Factors de risc
dc.subjectBacterièmia - Mortalitat
dc.subjectMalalties transmissibles
dc.subject.meshBacteremia
dc.subject.meshRisk Factors
dc.subject.meshCommunicable Diseases
dc.titleRisk factors for persistent enterococcal bacteraemia: a multicentre retrospective study
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.jgar.2022.05.003
dc.subject.decsbacteriemia
dc.subject.decsfactores de riesgo
dc.subject.decsenfermedades transmisibles
dc.relation.publishversionhttps://doi.org/10.1016/j.jgar.2022.05.003
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Bussini L, Rosselli Del Turco E] Infectious Disease Unit, IRCCS Policlinico di Sant'Orsola, Bologna, Italy. [Pasquini Z, Scolz K, Amedeo A, Beci G] Department of Medical and Surgical Science, Alma Mater Studiorum-Università di Bologna, Bologna, Italy. [Pericàs JM] Infectious Diseases Service, Hospital Clínic de Barcelona, Spain. Servei d’Hepatologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain
dc.identifier.pmid35569757
dc.identifier.wos000812167600003
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record